Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able to cure the disease. Furthermore, some therapies used are associated with side effects that can significantly decrease patients’ quality of life and can also prevent patients from receiving treatment. Hence, there is an unmet need for novel efficacious therapies with an improved safety and tolerability profile, and this Unmet Need module examines the key drivers of prescribing in this indication and analyses significant commercial opportunities.

Table of contents

  • Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis: Second- And Subsequent-Lines Advanced/Metastatic Colorectal Cancer
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Second- and Subsequent-Line Colorectal Cancer
        • Importance of Efficacy Attributes to Prescribing Decisions in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — Europe
        • Importance of Non-Clinical Factors to Prescribing Decisions in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — United States
        • Importance of Non-Clinical Factors to Prescribing Decisions in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer— Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, and Non-Clinical Attributes to Prescribing Decisions in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, and Non-Clinical Attributes to Prescribing Decisions in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — Europe
      • Abbreviations
      • Product Performance Against Treatment Drivers and Goals
        • Overview
        • Rationale for Drug Selection
          • Regimens for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer
        • Current Brand Performance on Key Treatment Drivers and Goals
          • Overall Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — United States
          • Overall Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — Europe
          • Relative Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Across Select Efficacy Attributes — United States
          • Relative Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Across Select Efficacy Attributes — Europe
          • Relative Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Across Select Safety and Tolerability Attributes — United States
          • Relative Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Across Select Safety and Tolerability Attributes — Europe
          • Relative Performance of Key Therapies for Second- and Subsequent-Line Advanced Metastatic Colorectal Cancer Across Select Non-Clinical Attributes — United States
          • Relative Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Across Select Non-Clinical Attributes — Europe
      • Assessment of Unmet Need
        • Overview
        • Overall Satisfaction with Current Treatment
          • Surveyed Oncologists' Satisfaction with the Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
          • Surveyed Oncologists' Satisfaction with the Performance of Key Therapies for Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
        • Physician Rating of Unmet Need in Second- and Subsequent-Lines Advanced/Metastatic Colorectal Cancer
          • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer— United States
          • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer— Europe
          • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — United States
          • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — Europe
          • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Second- and Subsequent-Line Advnaced/Metastatic Colorectal Cancer — United States
          • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer — Europe
        • Unmet Need in Second- and Subsequent-Lines Advanced/Metastatic Colorectal Cancer and Related Indications
          • Surveyed Oncologists' Ascribed Level of Unmet Need in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer and Related Indications — United States
          • Surveyed Oncologists' Ascribed Level of Unmet Need in Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer and Related Indications — Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Second- and Subsequent-Lines Advanced/Metastatic Colorectal Cancer Market and Emerging Therapy Insight
          • Opportunity: A Novel Therapy That Can Significantly Increase OS
          • Opportunity: A Novel Therapy That Improves PFS and/or ORR
          • Opportunity: A Therapy with an Improved Safety and Tolerability Profile
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
          • Assigned Prohibitions for the Conjoint Module
        • Attribute Importance and Part-Worth Utilities
          • Second- and Subsequnet-Line Advanced/Metastatic Colorectal Cancer Target Product Profile: Attribute Importance
          • Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Target Product Profile: Attribute-Level Part-Worth Utilities
        • Conjoint Analysis-Based Simulations of Market Scenarios
          • Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
          • Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
          • Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Market Simulations: Target Product Profiles Included in Scenario 1
          • Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
          • Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
          • Second- and Subsequent-Line Advanced/Metastatic Colorectal Cancer Market Simulations: Target Product Profiles Included in Scenario 2

    Author(s): Karen Pomeranz, PhD; Steven Tinsley, PhD, MSc

    Karen Pomeranz is a senior business insights analyst analyst in the oncology team at Decision Resources Group. She has worked on a breadth of indications including glioma, hepatocellular carcinoma, gastrointestinal stromal tumor, malignant melanoma, renal cell carcinoma, breast cancer, and colorectal cancer. She has worked on several products lines as well as with the Decision Resources Group consulting team on many projects.

    Her previous work experience includes conducting scientific research at Imperial College, London and Tel-Aviv University. Dr. Pomeranz holds an M.Sc. from Tel-Aviv University and a Ph.D. from Imperial College, London.

    Steven Tinsley, Ph.D., M.Sc., is a business insights analyst with the oncology division at Decision Resources Group.

    Dr. Tinsley obtained his doctorate in acute myeloid leukemia (AML) from University College London, where he focused on establishing the role of mutations in c-KIT in the pathogenesis and therapy of core-binding factor-related AML, and received his M.Sc. in stem cell technology and his B.Sc. in human genetics from the University of Nottingham. Prior to joining DRG, Dr. Tinsley was a grants adviser at the Wellcome Trust.


    Related Reports

    Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast

    Targeted therapies and various biomarkers (e.g., RAS,

    View Details

    Colorectal Cancer | Disease Landscape and Forecast | G7 | 2020

    Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented...

    View Details

    Colorectal Cancer - Geographic Focus: China - Colorectal Cancer - China In-Depth (China)

    Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal...

    View Details

    Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer

    This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatme...

    View Details